266 related articles for article (PubMed ID: 16105057)
21. Effect of a Probiotic Supplement Containing Lactobacillus Acidophilus and Bifidobacterium Animalis Lactis on Urine Oxalate in Calcium Stone Formers with Hyperoxaluria: A Randomized, Placebo-controlled, Double-blind and In-vitro Trial.
Tavasoli S; Jalali S; Naji M; Borumandnia N; Shakiba Majd G; Basiri A; Khosravi Darani K; Karamad D; Tajabadi-Ebrahimi M; Taheri M
Urol J; 2021 Jun; 19(3):179-188. PubMed ID: 34129232
[TBL] [Abstract][Full Text] [Related]
22. Enteric hyperoxaluria: role of microbiota and antibiotics.
Liu M; Nazzal L
Curr Opin Nephrol Hypertens; 2019 Jul; 28(4):352-359. PubMed ID: 31145706
[TBL] [Abstract][Full Text] [Related]
23. Dietary treatment of urinary risk factors for renal stone formation. A review of CLU Working Group.
Prezioso D; Strazzullo P; Lotti T; Bianchi G; Borghi L; Caione P; Carini M; Caudarella R; Ferraro M; Gambaro G; Gelosa M; Guttilla A; Illiano E; Martino M; Meschi T; Messa P; Miano R; Napodano G; Nouvenne A; Rendina D; Rocco F; Rosa M; Sanseverino R; Salerno A; Spatafora S; Tasca A; Ticinesi A; Travaglini F; Trinchieri A; Vespasiani G; Zattoni F;
Arch Ital Urol Androl; 2015 Jul; 87(2):105-20. PubMed ID: 26150027
[TBL] [Abstract][Full Text] [Related]
24. Pathophysiology and management of enteric hyperoxaluria.
Desenclos J; Forté V; Clément C; Daudon M; Letavernier E
Clin Res Hepatol Gastroenterol; 2024 May; 48(5):102322. PubMed ID: 38503362
[TBL] [Abstract][Full Text] [Related]
25. End Point Considerations for Clinical Trials in Enteric Hyperoxaluria.
Langman CB; Assimos D; Blank M; Calle J; Grauer A; Kausz A; Milliner D; Nazzal L; Smith K; Tasian G; Thompson A; Wood KD; Worcester E; Yang S; Malley MA; Knauf F; Lieske JC;
Clin J Am Soc Nephrol; 2023 Dec; 18(12):1637-1644. PubMed ID: 37342976
[TBL] [Abstract][Full Text] [Related]
26. A Double-Blind, Placebo Controlled, Randomized Phase 1 Cross-Over Study with ALLN-177, an Orally Administered Oxalate Degrading Enzyme.
Langman CB; Grujic D; Pease RM; Easter L; Nezzer J; Margolin A; Brettman L
Am J Nephrol; 2016; 44(2):150-8. PubMed ID: 27529510
[TBL] [Abstract][Full Text] [Related]
27. Urinary patterns of patients with renal stones associated with chronic inflammatory bowel disease.
Trinchieri A; Lizzano R; Castelnuovo C; Zanetti G; Pisani E
Arch Ital Urol Androl; 2002 Jun; 74(2):61-4. PubMed ID: 12161938
[TBL] [Abstract][Full Text] [Related]
28. In vitro anti-inflammatory activity of selected oxalate-degrading probiotic bacteria: potential applications in the prevention and treatment of hyperoxaluria.
Giardina S; Scilironi C; Michelotti A; Samuele A; Borella F; Daglia M; Marzatico F
J Food Sci; 2014 Mar; 79(3):M384-90. PubMed ID: 24471378
[TBL] [Abstract][Full Text] [Related]
29. What treatments reduce kidney stone risk in patients with bowel disease?
Bianco J; Chu F; Bergsland K; Coe F; Worcester E; Prochaska M
Urolithiasis; 2022 Oct; 50(5):557-565. PubMed ID: 35976425
[TBL] [Abstract][Full Text] [Related]
30. Treatment of enteric hyperoxaluria with calcium-containing organic marine hydrocolloid.
Lindsjö M; Fellström B; Ljunghall S; Wikström B; Danielson BG
Lancet; 1989 Sep; 2(8665):701-4. PubMed ID: 2570957
[TBL] [Abstract][Full Text] [Related]
31. Urinary lithogenic risk profile in recurrent stone formers with hyperoxaluria: a randomized controlled trial comparing DASH (Dietary Approaches to Stop Hypertension)-style and low-oxalate diets.
Noori N; Honarkar E; Goldfarb DS; Kalantar-Zadeh K; Taheri M; Shakhssalim N; Parvin M; Basiri A
Am J Kidney Dis; 2014 Mar; 63(3):456-63. PubMed ID: 24560157
[TBL] [Abstract][Full Text] [Related]
32. Oxalate metabolism in renal stone disease with special reference to calcium metabolism and intestinal absorption.
Lindsjö M
Scand J Urol Nephrol Suppl; 1989; 119():1-53. PubMed ID: 2669121
[TBL] [Abstract][Full Text] [Related]
33. The urinary response to an oral oxalate load in recurrent calcium stone formers.
Krishnamurthy MS; Hruska KA; Chandhoke PS
J Urol; 2003 Jun; 169(6):2030-3. PubMed ID: 12771711
[TBL] [Abstract][Full Text] [Related]
34. Association of absence of intestinal oxalate degrading bacteria with urinary calcium oxalate stone formation.
Mikami K; Akakura K; Takei K; Ueda T; Mizoguchi K; Noda M; Miyake M; Ito H
Int J Urol; 2003 Jun; 10(6):293-6. PubMed ID: 12757596
[TBL] [Abstract][Full Text] [Related]
35. Effect of dietary changes on urinary oxalate excretion and calcium oxalate supersaturation in patients with hyperoxaluric stone formation.
Penniston KL; Nakada SY
Urology; 2009 Mar; 73(3):484-9. PubMed ID: 19118878
[TBL] [Abstract][Full Text] [Related]
36. Enteric hyperoxaluria secondary to small bowel resection: use of computer simulation to characterize urinary risk factors for stone formation and assess potential treatment protocols.
Rodgers AL; Allie-Hamdulay S; Jackson GE; Sutton RA
J Endourol; 2014 Aug; 28(8):985-94. PubMed ID: 24773381
[TBL] [Abstract][Full Text] [Related]
37. Use of sevelamer hydrochloride as an oxalate binder.
Lieske JC; Regnier C; Dillon JJ
J Urol; 2008 Apr; 179(4):1407-10. PubMed ID: 18289565
[TBL] [Abstract][Full Text] [Related]
38. Diet and renal stone formation.
Trinchieri A
Minerva Med; 2013 Feb; 104(1):41-54. PubMed ID: 23392537
[TBL] [Abstract][Full Text] [Related]
39. Intestinal absorption of oxalate and calcium in patients with jejunoileal bypass.
Lindsjö M; Danielson BG; Fellström B; Lithell H; Ljunghall S
Scand J Urol Nephrol; 1989; 23(4):283-9. PubMed ID: 2595324
[TBL] [Abstract][Full Text] [Related]
40. Effects of Lactobacillus casei and Bifidobacterium breve on urinary oxalate excretion in nephrolithiasis patients.
Ferraz RR; Marques NC; Froeder L; Menon VB; Siliano PR; Baxmann AC; Heilberg IP
Urol Res; 2009 Apr; 37(2):95-100. PubMed ID: 19214493
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
